Literature DB >> 21180572

Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis.

J Theodore Phillips1, Elliot M Frohman.   

Abstract

Entities:  

Year:  2008        PMID: 21180572      PMCID: PMC3002555          DOI: 10.1177/1756285608099124

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


× No keyword cloud information.
  11 in total

1.  Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

Authors:  D S Goodin; E M Frohman; G P Garmany; J Halper; W H Likosky; F D Lublin; D H Silberberg; W H Stuart; S van den Noort
Journal:  Neurology       Date:  2002-01-22       Impact factor: 9.910

2.  Immune surveillance in multiple sclerosis patients treated with natalizumab.

Authors:  Olaf Stüve; Christina M Marra; Keith R Jerome; Linda Cook; Petra D Cravens; Sabine Cepok; Elliot M Frohman; J Theodore Phillips; Gabriele Arendt; Bernhard Hemmer; Nancy L Monson; Michael K Racke
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

Review 3.  Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.

Authors:  Elliot M Frohman; Olaf Stüve; Eva Havrdova; John Corboy; Anat Achiron; Robert Zivadinov; Per Soelberg Sorensen; J Theodore Phillips; Brian Weinshenker; Kathleen Hawker; Hans-Peter Hartung; Lawrence Steinman; Scott Zamvil; Bruce A C Cree; Stephen Hauser; Howard Weiner; Michael K Racke; Massimo Filippi
Journal:  Arch Neurol       Date:  2005-10

4.  Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.

Authors:  Olaf Stüve; Christina M Marra; Amit Bar-Or; Masaaki Niino; Petra D Cravens; Sabine Cepok; Elliot M Frohman; J Theodore Phillips; Gabriele Arendt; Keith R Jerome; Linda Cook; Francois Grand'Maison; Bernhard Hemmer; Nancy L Monson; Michael K Racke
Journal:  Arch Neurol       Date:  2006-10

5.  Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.

Authors:  L J Balcer; S L Galetta; P A Calabresi; C Confavreux; G Giovannoni; E Havrdova; M Hutchinson; L Kappos; F D Lublin; D H Miller; P W O'Connor; J T Phillips; C H Polman; E-W Radue; R A Rudick; W H Stuart; A Wajgt; B Weinstock-Guttman; D R Wynn; F Lynn; M A Panzara
Journal:  Neurology       Date:  2007-04-17       Impact factor: 9.910

6.  Quantitative risk-benefit analysis of natalizumab.

Authors:  J P Thompson; K Noyes; E R Dorsey; S R Schwid; R G Holloway
Journal:  Neurology       Date:  2008-07-29       Impact factor: 9.910

7.  Health-related quality of life in multiple sclerosis: effects of natalizumab.

Authors:  Richard A Rudick; Deborah Miller; Steve Hass; Michael Hutchinson; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Ludwig Kappos; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
Journal:  Ann Neurol       Date:  2007-10       Impact factor: 10.422

8.  Infusion-related hypersensitivity reactions during natalizumab treatment.

Authors:  J T Phillips; P W O'Connor; E Havrdova; M Hutchinson; L Kappos; D H Miller; C H Polman; F D Lublin; G Giovannoni; A Wajgt; F Lynn; M A Panzara; A W Sandrock
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

9.  Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

Authors:  Tarek A Yousry; Eugene O Major; Caroline Ryschkewitsch; Gary Fahle; Steven Fischer; Jean Hou; Blanche Curfman; Katherine Miszkiel; Nicole Mueller-Lenke; Esther Sanchez; Frederik Barkhof; Ernst-Wilhelm Radue; Hans R Jäger; David B Clifford
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

10.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

View more
  1 in total

1.  Escalating immunotherapy of multiple sclerosis.

Authors:  Peter Rieckmann; Anthony Traboulsee; Virginia Devonshire; Joel Oger
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.